Furthermore, a study by Corcoran et al. [218] found that patients with BRAF-V600E-mutated CRC, when treated with a triplet regimen (dabrafenib, trametinib, and panitumumab), produced a better response rate in comparison with the double regimens (dabrafenib + panitumumab or trametinib + panitumumab). Here, BRAF is linked to colorectal carcinoma.